Understand morning testosterone samples, repeat testing, assay accuracy and SHBG, plus questions to bring to a clinician after a low result.
A structured testosterone evaluation helps clarify whether symptoms and repeated blood results support a hormone deficiency or whether testing conditions need closer review.
This article is for informational purposes only and is not medical advice. A qualified clinician should assess personal symptoms and decide which tests or follow-up are appropriate.
The EAU guideline on male hypogonadism recommends a reliable total-testosterone measurement under defined collection conditions. Before testing, the relevant preparation points are:
The clinician or laboratory should clarify the practical fasting instructions before collection. A night-shift schedule or current illness also belongs in that conversation rather than being treated as an incidental detail.
The aim is an interpretable measurement, not the highest possible number. Collection conditions become part of the information the clinician uses when reviewing the result.
The EAU framework combines clinical assessment with laboratory evidence. The following sequence explains the main stages without turning them into a personal testing plan.
The evaluation begins with relevant symptoms and signs. The EAU describes late-onset hypogonadism as requiring persistent, specific symptoms alongside biochemical evidence of testosterone deficiency. It also cautions that symptoms are not unique to this condition and may have other explanations.
The review includes other illnesses and any drugs or substances that could affect testosterone. Understanding how symptoms fit into a hormone assessment helps explain why the clinical conversation comes before interpreting a number.
Collection follows the timing and fasting conditions described above. For someone working nights, the clinician considers the sleep-related sampling guidance rather than automatically applying the usual morning window.
Total testosterone is the initial measurement specified in the guideline's testing recommendations. Information about collection time and fasting status remains relevant when the result returns. Those details help the clinician assess whether the sample was obtained under the intended conditions.
An assay is the laboratory method used to obtain the measurement. The EAU recommends a reliable assay because the testing method is part of the evidence behind the reported concentration.
This stage produces the numerical result that will enter the clinical review. When a result is close to a decision threshold, asking which method was used becomes particularly relevant. The assay considerations are explained in more detail below.
When total testosterone is below 12 nmol/L, the EAU recommends repeat measurements on at least two separate occasions. It gives 12 nmol/L (3.5 ng/mL) as a threshold for diagnosing late-onset hypogonadism within its wider diagnostic framework.
The guideline also calls for confirmation of a pathological initial result before testosterone therapy begins. This is why follow-up after a low testosterone result is part of the evaluation rather than an optional check on an already settled diagnosis. The repeat measurement belongs alongside the clinical assessment established at the first stage.
A total-testosterone result near the lower limit may prompt a question about additional interpretation. The same applies when SHBG may be altered.
The EAU recommends measuring SHBG and considering a free-testosterone calculation when SHBG is altered. These measurements address a specific interpretation question rather than creating a requirement for every patient to receive an identical panel. The clinician decides whether they would add useful information to the existing findings.
Depending on the clinical picture, the EAU says evaluation may include LH, FSH or prolactin. These tests are considered alongside the symptoms and testosterone findings.
Their inclusion should answer a clinical question rather than simply make the report longer. A useful discussion with the ordering clinician is what each additional measurement is intended to clarify. The approved framework does not require every listed hormone test for every man undergoing an initial assessment.
The laboratory output provides a measured testosterone concentration. For interpretation, that value needs to remain attached to its units and the reporting laboratory's reference range.
If SHBG or free testosterone was assessed, those findings also belong in the review. The method used to measure or calculate free testosterone is relevant information, not merely a technical footnote.
The EAU's approach connects the report with the clinical history and collection conditions. A physician's review brings together several questions:
These are questions for a clinical review rather than a checklist for assigning a diagnosis at home. For the patient, the practical task is to provide the report and the circumstances surrounding collection so the clinician can assess them together.
The EAU identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also says standardized automated immunoassays for total testosterone correlate well with LC-MS/MS.
Those statements do not make the assay name irrelevant. They support asking how the laboratory method and its reference range relate to the result under discussion, particularly when the value is near a clinical decision threshold.
An assay-performance study published in 2026 illustrates why this matters. Its authors found that accuracy-based testing could reveal bias and imprecision that may affect classification near a threshold. The study used commutable samples and reference-method targets to examine measurement performance.
The study covered a limited set of samples and methods. Its threshold exercise did not independently establish clinical diagnoses and should not be presented as a population-wide misdiagnosis rate. The practical question is whether method-related uncertainty matters for the particular result being reviewed.
The EAU notes that total testosterone can be influenced by SHBG. It lists obesity and hypothyroidism among factors associated with lower SHBG. Insulin resistance and some medications are also included.
This is why a clinician may look beyond total testosterone when SHBG is altered. The relevant question is whether SHBG measurement and free-testosterone assessment would help explain the findings in context.
The method matters here as well. The EAU identifies equilibrium dialysis as the most accurate method for measuring free testosterone. It says available immunoassays do not accurately estimate free testosterone and recommends considering a calculation when SHBG is altered.
A report labelled “free testosterone” therefore deserves a method-specific discussion. Ask whether the result was calculated or measured and how that approach fits the clinical question. Further background on the relationship between total testosterone, free testosterone and SHBG can make that conversation easier to follow.
Once results are available, arrange a review with the ordering clinician. Bring the complete report and information about the collection time, fasting status and any acute illness. Make sure the clinician knows about night-shift work and relevant medicines or substances.
Ask whether confirmation is needed and whether SHBG or other indicated tests would resolve a specific uncertainty. Leave the appointment with an explanation of what the findings support and what remains to be assessed, rather than a treatment decision based only on a laboratory number.
Testosterone workups are coordinated by a qualified clinician, while Testostra makes the accompanying hormone terminology easier to follow. For readers puzzled by total testosterone, free testosterone or SHBG, its evidence-led reporting connects these measurements with the wider testing discussion while leaving individual medical decisions to qualified care.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra